# moderate-to-severe AD FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/moderate-to-severe-ad

> 1 upcoming FDA catalyst in moderate-to-severe AD: TRB-061 (TRXB) on 2H 2027 (trial start).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA decisions for moderate-to-severe AD?

1 upcoming FDA catalyst in moderate-to-severe AD: TRB-061 (TRXB) on 2H 2027 (trial start). SEC prospectus (424B): "Assuming supporting results and subject to regulatory submission and feedback, we expect to commence a Phase 2 clinical trial of TRB-061 in adult patients with moderate-to-severe AD at multiple sites in the United States and globally in the second half of 2027." [Calendar and source filings](https://sec-api.dev/indications/moderate-to-severe-ad)

Source: SEC prospectus (424B), accession 0001193125-26-419203, https://www.sec.gov/Archives/edgar/data/2139097/000119312526419203/project_dino_-_424b4.htm (retrieved 2026-11-12). Last confirmed 2026-10-09. Cite: https://sec-api.dev/indications/moderate-to-severe-ad#answer

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| July 29, 2025 | [Modzatinib topline data readout](https://sec-api.dev/pdufa/modzatinib) | ACRS | moderate-to-severe AD | completed, positive | "WAYNE, Pa., July 29, 2025 -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced positive top-line results from its open-label, single-arm Phase 2a trial of ATI-2138, a potent and selective investigational oral covalent inhibitor of interleukin-2-inducible T cell kinase (ITK) and Janus kinase 3 (JAK3), in 14 patients with moderate-to-severe atopic dermatitis (AD)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1557746/000155837025009739/acrs-20250729xex99d2.htm)) |
| Jul 2026 | [BBT001 topline data readout](https://sec-api.dev/pdufa/bbt001) | BBTX | moderate-to-severe AD | completed, positive | "We are currently evaluating BBT001 for the treatment of moderate-to-severe AD in our Global BBT001 Study and China AD Study and reported positive topline 4-week PoC bio-naïve AD data from our Global BBT001 Study in July 2026." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/2044950/000162828026068563/bambusa-424b4.htm)) |
| late 2026 | [KT-621 topline data readout](https://sec-api.dev/pdufa/kt-621) | KYMR | moderate to severe AD | scheduled | "The Company plans to report topline data by year-end 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1815442/000119312526436965/kymr-ex99_1.htm)) |
| 2H 2027 | [TRB-061 trial start](https://sec-api.dev/pdufa/trb-061) | TRXB | moderate-to-severe AD | scheduled | "Assuming supporting results and subject to regulatory submission and feedback, we expect to commence a Phase 2 clinical trial of TRB-061 in adult patients with moderate-to-severe AD at multiple sites in the United States and globally in the second half of 2027." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/2139097/000119312526419203/project_dino_-_424b4.htm)) |

## Drugs

- [Modzatinib](https://sec-api.dev/pdufa/modzatinib) (ACRS)
- [BBT001](https://sec-api.dev/pdufa/bbt001) (BBTX)
- [KT-621](https://sec-api.dev/pdufa/kt-621) (KYMR)
- [TRB-061](https://sec-api.dev/pdufa/trb-061) (TRXB)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/moderate-to-severe-ad.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "moderate-to-severe AD FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/moderate-to-severe-ad

```bibtex
@misc{secapidev_indications_moderate_to_severe_ad_20261116,
  title        = {moderate-to-severe AD FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/moderate-to-severe-ad}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_moderate_to_severe_ad_20261116","title":"moderate-to-severe AD FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/moderate-to-severe-ad","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
